EXOZ · Exozymes Inc.
$5.82
-0.18 (-3.00%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Given the Company's current operating cash burn, its existing working capital as of June 30, 2026, is not sufficient to fund operations for twelve months from the date these condensed unaudited consolidated financial statements are issued, and management has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$54.02M
Shares
9.28M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$70.07K
FY2023
Net Income
-$9.16M
-56.3%
FY2025
Operating Margin
-2563.5%
FY2023
Diluted EPS
-$1.09
-22.5%
FY2025
Operating Cash Flow
-$6.5M
+23.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | — | — | $70.07K | |
| $4.89M | $3.71M | $1.87M | $527.48K | |
| $5.67M | $6.01M | $4.06M | $1.34M | |
| -$10.56M | -$9.72M | -$5.93M | -$1.8M | |
| — | — | — | -2563.5% | |
| — | $88.75K | -$6834 | — | |
| -$10.3M | -$9.26M | -$5.86M | -$2M | |
| — | -$105.21K | — | $42.27K | |
| -$10.19M | -$9.16M | -$5.86M | -$2.04M | |
| — | — | — | -2909.12% | |
| USD/shares | — | -$1.09 | -$0.89 | -$0.33 |
| USD/shares | — | -$1.09 | -$0.89 | -$0.33 |
| shares | — | 8.38M | 6.56M | 6.25M |
| shares | — | 8.38M | 6.56M | 6.25M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.11×
EV/EBIT
—
Peer median 12.01×
P/E (TTM)
—
Peer median 8.45×
Peer medians compare against the 300 similar-size Biotechnology companies (of 545 listed).